Hosted on MSN2mon
FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatmentThe company states: “Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for lecanemab-irmb – U.S. brand name: LEQEMBI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback